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Abstract
Background: In addiction care, urine drug screening tests are recommended to assess psychoactive substances
use. While intrinsic diagnostic value of these tests is demonstrated, the consequences of carrying out these tests on
opiate maintenance treatment (OMT) have not been established. The main objective will be to assess the impact of
on-site urine drug screening tests (OS-UDS) in general practice compared to routine medical care on OMT retention
at 6 months in opioid-dependent patients initiating buprenorphine.
Methods/Design: The ESUB-MG study uses a pragmatic, cluster randomized controlled trial design. General Practitioners
(GPs) regularly managing patients treated with buprenorphine and consenting for participating will be invited to
participate. GPs will be randomly assigned to one of two groups for 6 to 24 months: (a) control group (usual care:
standard medical strategy for assessing drug use); (b) interventional group (including 1/ a training session on practice
and interpretation of OS-UDS; 2/ the supply of OS-UDS at GPs’ medical offices; 3/ performing an OS-UDS before the
first prescription of buprénorphine). GPs will have to include 1 to 10 patients aged 18 years-old or more, consulting for
starting treatment by buprenorphine, not opposed to participate. The primary outcome will be OMT retention at
6 months.
Discussion: This randomized interventional trial should bring sufficient level of evidence to assess effectiveness of
performing OS-UDS in general practice for patients treated by buprenorphine. Training GPs to drug tests and supplying
them in their office should lead to an improvement of opioid-addicted patients’ care through helping decision.
Trials registration: NCT02345655 (first registration May 14, 2014)
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Background
Opioid addiction is currently defined as a “chronic, re-
lapsing disorder” [1, 2]. Mortality of untreated heroin
dependence is consistently estimated at 1–3 % per year,
at least half of which is because of heroin overdose [3].
Beyond mortality and morbidity, heroin dependence in-
flicts enormous social and economic costs due to crime,
unemployment, relationship breakdown, and the cost of
law enforcement. Data from systematic reviews show
that methadone maintenance is the most effective treat-
ment in retaining patients in treatment and suppressing
heroin use [4, 5]. The systematic review by Mattick et al.
demonstrated the efficacy of buprenorphine maintenance
treatment, with a lower retention rate than methadone but
giving a similar decrease in opiate consumption [5]. The
combination of buprenorphine and naloxone (marketed as
Suboxone®) was created to prevent the injection of bupre-
norphine. Nevertheless, its effectiveness in preventing
intravenous use of buprenorphine is not yet clear [6, 7].
The management of opiate-dependent patients in France
is shared among specialized centres and general practi-
tioners (GPs). Three drugs are available for the mainten-
ance treatment methadone, buprenorphine (approved
since 1995) and buprenorphine-naloxone (approved since
2006). Methadone must be initially prescribed by practi-
tioners in specialized addiction centers, whereas buprenor-
phine and buprenorphine-naloxone should be prescribed
by any general practitioner and available through com-
munity pharmacies. The number of people receiving
maintenance treatment was estimated around 100,000
for high-dose buprenorphine and around 40,000 for
methadone in 2010 [8]. Because the availability and the
easy access to buprenorphine [9] most of opiate-dependent
patients are managed in general practice [10]. Actually, few
GPs take care of these patients: they were only 24 % in
2009 to regularly take care of patients under opiate main-
tenance treatment (OMT) [11]. One of their difficulties is
to evaluate the concordance between the patient’s word
and his drug use (OMT and other illicit drugs) [12] while
associated drug use is frequent (at least one or two thirds
of patients under OMT would also consume alcohol and
benzodiazepines [13]).
In the field of addiction, assessment of substances con-
sumption is crucial for diagnosis and, even more, for med-
ical management. Nevertheless, this assessment is often
difficult as self-reports use to under estimate psychoactive
substances’ consumption [14–18]. One Scandinavian study
in 2009 [19] compared the assessment by the psychiatrist
of drug consumption in an emergency setting to that ob-
tained by a urine drug screening test (UDT); the reference
method being chromatography-tandem mass spectrom-
etry. The physician had correctly assessed the consump-
tion of alcohol but the assessment for illicit substances
was not so good for other- psychoactive substances. The
value of urine drug screening was assessed comparing
urine screening tests’ results and chromatography. At the
same time, urine drug screening presented a better sensi-
tivity for benzodiazepines, opiates and cannabis. This
study clearly showed that physicians’ assessment of psy-
choactive drug use lead to underestimate the true con-
sumptions, and UDT would be useful in making decisions
about treatment.
By contrast, in certain context, patients can overesti-
mate their use of psychoactive substances notably when
entering a detoxification program [20].
French guidelines highlight the need to assess opiate de-
pendence for the management of patients taking OMT:
screening tests have to be performed before introducing
methadone; they are recommended before starting treat-
ment with buprenorphine and during the follow up of
both treatments [21]. Methadone prescription guidelines
detail the recommended urine tests: a first, mandatory test
before starting methadone treatment and later control
tests. The first urine test confirms current drug consump-
tion and the absence of methadone intake. Tests are sub-
sequently done once or twice a week during the first
3 months of treatment, then twice monthly. When the
patient has transferred to an outpatient setting, tests can
be done if the physician considers it necessary. Tests are
not obligatory for buprenorphine, but highly recom-
mended. In 2011, French guidelines advised a standard-
ized screening test schedule in the initiation and follow-up
of buprenorphine treatment [22].
The drug tests can be carried out by immunochemical
methods, either by automated analyzers in the biology la-
boratory or by drug screening kits. These tests (whether
on a laboratory automat or using a commercial kit) are
qualitative and have defined thresholds. False negatives
exist for cocaine and benzodiazepines in particular, but
test quality is intrinsically better for opiate detection
(1.9 % false negatives) [23]. Results can be confirmed by
the reference method, liquid or gas phase chromatography
with mass spectrometry, which gives quantitative mea-
surements [24]. Screening can be done during the patient’s
visit, in either a specialized addiction centre or the physi-
cian’s office. Laboratory tests, regardless of the method or
the biological medium, are reimbursed by the French
health insurance system with no limit on their number or
time period. In medical offices, immunoassays have been
shown to be reliable [25, 26]; nevertheless, on-site urine
drug screening (OS-UDS) by commercial kits are not re-
imbursed by the French health insurance system but some
specialized addiction networks in France provide them to
their members.
In a recent study performed among a sample of French
GPs, only 12.2 % of GPs reported to perform urinary
screening tests and in this proportion were counted GPs
who reported to use them for other reasons than initiation
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and follow up of OMT [11]. The main reason for not per-
forming UDS was a lack of knowledge about screening
tests [11]. Among the few GPs using tests, the conse-
quence they reported was mainly reinforcing dialogue
with the patient. In another study performed in the same
area among 1,507 patients initiating an OMT with bupre-
norphine or methadone, only 2.6 % had at least a drug test
reimbursed by the Health Insurance System during their
addiction treatment period [27].
Few studies explored the consequences of carrying out
these tests on medical management. In the previous
cited study, having been drug tested was associated with
a better opiate substitution maintenance, with 45 % de-
crease of drop-outs (95 % CI: 0.38–0.80) [27]. In a retro-
spective cohort study of methadone users performed
through data obtained from a primary care prescription
registry in Tayside, Scotland, a history of having urine
tested was a protective factor in relation to all-cause
mortality with a reduction of 70 % of risk of death (HR
0.33, 0.22 to 0.49) [28]. On the basis of the literature,
one would suppose that carrying out UDS would provide
an improvement in the management of patients with
opioid addiction and positive outcomes for patients such
as longer opiate substitution maintenance and its clinical
consequences in which a decrease in mortality. However,
this hypothesis relies only on observational data, and we
cannot rule out confusion bias.
In order to provide more consolidated data on the
interest of using UDT in the context of general practice,
we propose an interventional trial, which the main ob-
jective is to assess the impact of on-site urine drug
screening tests in general practice compared to routine
medical care on OMT retention at 6 months in opioid-
dependent patients initiating buprenorphine. Second ob-
jectives are to assess the acceptability of OS-UDS by pa-
tients and GPs, to assess patient adherence to




The ESUB-MG study is a pragmatic, cluster randomized
controlled trial design. Clustering is at the level of the
GP. A cluster design is needed as the intervention con-
cerns the GP and as the evaluation concerns the patient.
Furthermore, patients of a same GP are more correlated
than patients of different GPs.
Research objectives
This study is designed to assess the impact of on-site
urine drug screening tests in general practice compared
to routine medical care on OMT retention at 6 months
in opioid-dependent patients initiating buprenorphine.
Study population
GP inclusion criteria
Professional criteria: to practice as a GP, to be in activity,
to practice in general ambulatory practice (in a medical
office).
Patients’ characteristics: to regularly manage patients
treated with buprenorphine.
Legal characteristic: to be registered in sector 1 (a regis-
tered doctor has an agreement with Social Security and
the fees he applies correspond to ‘reasonable and tactful’
tariffs set by the social security system, whereas a non-
registered doctor is authorised to charge higher fees. A
sector 1 registered general practitioner charges no more
than the statutory fee).
Consent for participating to the trial.
GPs exclusion criteria
To practice in a group medical office in which another GP
has been included in the trial.
Patients' inclusion criteria
Aged 18 years-old or more.
To consult for starting buprenorphine or
buprenorphine-naloxone (as several periods of OMT
exist for a same period, a period of more than 6 months
without OMT will be sufficient to consider that a patient
starts buprenorphine or buprenorphine-naloxone).
Affiliated to a health insurance scheme.
Not opposed to participate.
Patients’ exclusion criteria
To consult for continuing buprenorphine or for
another complain related to opiate substitution
treatment.
To be known and yet managed by the GP for an opiate
maintenance treatment.
To have started buprenorphine or buprenorphine-
naloxone in a specialized centre or in a hospital.
To be treated with methadone.
To be treated with methadone and asking a switch
toward buprenorphine or buprenorphine-naloxone.
Not consenting to participate to the study.
Recruitment
GPs recruitment
Six academic general medicine departments and six centers
for evaluation and information on pharmacodependence-
addictovigilance (CEIP-A) will work in pairs to recruit vol-
untary GPs within their network of working GPs and
through regional addiction networks.
Recently, in France, general medicine was recognized
as a specialty with a specific training. Consecutively, aca-
demic general medicine departments were developed in
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each faculty. In 2008, an academic pathway of general
medicine was created.
In order to assist the French health authorities, in
charge of the monitoring and the scheduling of psycho-
active substances with abuse potential, a monitoring sys-
tem for psychoactive medications abuse consisting of a
national network of 13 centers for evaluation and infor-
mation on pharmacodependence-addictovigilance (CEIP-
A) was created in 1990 [29, 30].
In both sources for selection, GPs will be contacted by
postal mail comprising a questionnaire for validating in-
clusion criteria for the GP, and an agreement form for
participating to the ESUB-MG study. A pre-stamped re-
turn envelope will be included. Monetary compensation
is planned for participating GPs as compensation for the
time and contribution to the study.
GPs in both groups will receive both oral and written
information about study design and conduct (patients’
recruitment, inclusion criteria). Material for data collec-
tion will comprise a GP questionnaire on basic demo-
graphic information and location, GP information notice
(detail on recruitment and study conduct), questionnaire
for the inclusion and follow up visit.
GPs agreeing to participate to the study will be ran-
domly assigned to one of two groups: one group with
intervention, one control group.
Patients’ recruitment
GPs will be requested to include all consecutive patients
that would be eligible. Each GP have to include at least
two patients within 18 months.
Participant recruitment will commence in March
2016, and patient participation will be completed by
August 2018. The planned end date for the trial is
December 2019.
Consent
GPs will inform eligible patients of their involvement in
the study and that their medical data will be used for the
purpose of the research. As a research on standard care
GPs will have to ensure that patient are not opposed to
take part to the research.
Patients that would explicitly express their opposition
will not be included. Patients who are not opposed to
participate but refusing to submit to one or several OS-
UDS will be maintained in their group defined by their
cluster.
Randomization
Randomization will be undertaken at the cluster (GP)
level. Based on the procedure allocated to GP, all pa-
tients within a cluster will be assigned to either interven-
tion or control group.
Randomization of participating GP will be performed
after GP’s approval and collecting complete question-
naire including basic demographic information and their
location. The randomization list will be generated by an
independent biostatistician in the clinical research meth-
odological support unit (Unité de Soutien Méthodologi-
que à la Recherche Clinique USMR) of the University
hospital (Centre Hospitalier Universitaire CHU) of
Toulouse, France. Clusters will not be randomized all
at once (first patients inclusion need to begin whereas
GPs’ recruitment will be on-going), thus the allocation
for each consecutive participating GP will be obtained
from the USMR through a specific website. To avoid
contamination bias, no more than one GP could be in-
cluded in a given medical practice.
Intervention
Intervention will consist in: 1) a training session for GPs
on use and interpretation of OS-UDS; 2) the supply of
OS-UDS at GPs’ medical offices; 3) performing an OS-
UDS before the first prescription of buprenorphine. GPs
will be let free to perform OS-UDS for the follow-up if
they judge it necessary.
GP assigned to the intervention group will be visited
by a clinical research assistant (CRA) to be trained on
the methods for performing test (urinary sample collec-
tion and reading of the test results). The training session
is expected to last about 1 h, and a written guidance will
be provided. Material for testing (OS-UDS) will also be
supplied during this session. OS-UDSs will be centrally
bought by the CHU de Toulouse and will be provided by
the CRA in charge of the training session.
During the consult, GPs of the intervention group will
dedicate an average 5 min to perform OS-UDS. Patients
will be asked to collect a urine sample at the GP’s med-
ical office. GP will read and communicate the results im-
mediately to the patients. GPs will keep free of their
management according to OS-UDS results.
OS-UDS characteristics
OS-UDS will be in accordance with positivity threshold
recommended by the National Institute on Drug Abuse
(NIDA) [31] and the Substance Abuse and Mental Health
Administration (SAMSHA) [32]. The SAMSHA increase
the threshold for screening opiates in 2008 (2000 ng/mL
instead of 300 ng/mL) to avoid false positive to ingestion
of poppy-seeds. Nevertheless, many laboratories main-
tained the threshold of 300 ng/mL to preserve the opiates
screening sensibility [33]. Thus, we will use the threshold
of 300 ng/mL.
Several substances will be screened through the OS-
UDS in our study: buprenorphine, methadone’s metabol-
ite, 2-ethylidine-1,5-dimethyl-3,3 diphenylpyrrolidine
(EDDP), opiates, and cocaine. Opiate substitutes should
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be systematically screened before starting buprenor-
phine, according to guidelines. Buprenorphine screen-
ing is intended to assess adherence to OMT after
initiation, whereas opiates are screened to monitor con-
comitant consumptions over the course of OMT, or to
confirm an opiate addiction before the first prescription
(which confirms the indication of OMT). Methadone
screening is intended to rule out an ongoing treatment
by methadone. Cocaine is often consumed with opiates.
In France, at least 10 % of patients would be concerned by
cocaine consumption while they are treated with an opioid
substitute [34, 35], and it is associated with negative out-
come. Some patients could request for an OMT being un-
aware of the indication of these drugs and believing they
could be offered such treatment.
Positivity thresholds currently used [31, 32] and that
we will use are: buprenorphine: 10 ng/mL ; EDDP (the
metabolite of methadone): 100 ng/mL ; opiates: 300 ng/
mL ; cocaine: 300 ng/mL.
At these thresholds, sensibility was 80 % (IC 95 %: 55–
100) and specificity 99 % [96 – 100] for opiates, sensibility
not calculable and specificity 100 % [100–100] for cocaine
[19]. In another study, sensibility for buprenorphine with
3 different OS-UDS varied from 88 to 100 % and specifi-
city from 91 to 100 % [36].
Controlled group
Controlled arm will correspond to standard medical
strategy for assessing consumptions while prescribing
OMT. Excluding OS-UDS, there will be no prohibited
procedure. In particular, GPs of the controlled harm are
authorized to implement any biological test to ascertain
associated substances use, including for instance labora-
tory testing. However, according to previous data, we
can expected that few drug tests should be performed in
this control group: 1 to 3 % [11, 27].
Outcome measures
The primary outcome will be OMT retention at 6 months.
Secondary outcomes will be patient adherence to bupre-
norphine, associated psychoactive substances use, accept-
ability of OS-UDS reported by the patient, acceptability of
OS-UDS reported by the GP.
Primary outcome
Retention in treatment at 6 months will be the main
judgment criterion. Actually, a review on all Cochrane
systematic reviews performed by the Cochrane Review
Group on Drugs and Alcohol highlighted that the main
outcomes used in studies assessing effectiveness of opi-
ate maintenance treatment were retention in treatment
and illicit use of heroin [4]. Whatever the treatments
compared, the retention in treatment was the most con-
stant and the most reproducible outcome used over the
different clinical trials because heroin use (assessed
through different ways, self-reported or through urinary
analysis) is rarely reported in a standardized way. This
outcome could be considered as intermediate steps of
treatment for heroin-addicted patients. Because observa-
tional studies showed high rates of mortality in heroin-
addicted patients [37], especially early after discharge
from treatment, the ability of a treatment in retaining
people in treatment should be reported as a proxy of ef-
fectiveness [38].
Retention in treatment will be defined as patients
remaining under opiate maintenance treatment at 6 months
in a context of medical care (i.e. drug prescribed by a phys-
ician, not diverted or obtained through an illegal way,
whatever the drug considered, buprenorphine; buprenor-
phine/naloxone, methadone) and assessed by the general
practitioner at the end of the follow-up. Patients switching
from buprenorphine to methadone or to buprenorphine/
naloxone during study follow-up will be considered as
remaining under opiate maintenance treatment.
The patient will be defined as retained in treatment if
he will be prescribed by the same GP a legal opiate
maintenance drug, or if the drug will be prescribed by
another practitioner in connection with the treating
physician. In case of loss of follow-up or diverted use of
drug (intravenous or nasal route or illegal acquisition of
the OMT drug), the patient will be considered as not
retained. In case of death, the patient will be considered
as maintained until the date of death, and censored after
this date. Buprenorphine must be prescribed under strict
conditions for a maximum of 28 days (methadone for a
maximum of 14 days). Consequently, a patient not at-
tending a medical visit for more than 56 days (2 months)
should be considered as not remaining under opiate
maintenance treatment.
Retention in treatment has to be recorded at 6 months
(time window tolerated of +/− 14 days) as there is no
scheduled or mandatory visit for the patient.
Secondary outcomes
The secondary judgment criteria will be the adherence
to buprenorphine associated psychoactive substances
use, and acceptability of OS-UDS reported by the pa-
tient, the GP.
We will specifically collect for both groups: characteristics
of buprenorphine utilization (dose, duration), exposure to
opiate or other illegal substances (heroin, morphine, canna-
bis, cocaine, benzodiazepines, amphetamines, other…)
during the follow-up (self-reported during medical examin-
ation and/or biologically assessed); for the intervention
group: number of OS-UDS performed by GP and by pa-
tient acceptability reported by the patient and by the GP
(self-reported questionnaires).
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Cross-link data
To ensure completeness in prescription drug records,
significant medical event and death occurring during fol-
low up, additional information on medical care will also
be obtained through the database of the health insurance
scheme. A query into the information system from the
national health insurance scheme database (SNIIRAM)
and national mortality registry will be done to complete
follow-up [39]. Patients will be matched thanks to a
probabilistic match [40]. In a recent study, around 80 %
of patients had been matched between general practice
data and health insurance scheme data [41]. Data col-
lected will not be included in the main analysis.
Sample size calculation
Comparisons between groups will be performed taking
into account clustering which the unity will be the GP.
Thus the sample size must be corrected by an inflation
factor according to guidelines on clustered analyses
[42–45]. According to the results of a previous study
performed by our group on patients initiating bupre-
norphine in ambulatory care in the Midi-Pyrénées area
[27], we were able to identify clusters of GPs and calcu-
lated the intra-cluster correlation coefficient (CCI = 2.79 %)
and the mean cluster size (m = 2), giving an inflation factor
(IF = 1.03).
According to the literature, the retention rate with
buprenorphine at 6 months is generally around 40 %,
with 60 % in specialized addiction centers with urinary
testing and supervision [4, 5]. In studies performed in
our area, observed retention rates were similar [13].
Using reimbursement data from the French Health In-
surance system at the regional level, we compared reten-
tion rate of patients newly treated by buprenorphine
according to performing or not urinary testing [27]. In
this study including 1,507 subjects followed-up over
30 months, the retention rate in patients with urinary
testing was significantly better than the reference
group, with an adjusted Hazard Ratio of 0.55 (95 %
CI: 0.38–0.80).
Thus, considering a retention rate in the reference
group of 36 %, and an expected retention rate of 50 % in
the intervention group, if mean cluster size (m) = 2, α
risk = 0.05 and β risk = 0.20, the theoretical formula of
Hayes and Moulton gives 100 clusters by group, i.e. 100
GPs in each group, corresponding to 200 patients in
each group, i.e. 400 patients in all [45].
Recruiting 2 patients by GPs over a period of 18 months
seems realistic, even if these GPs are not working in an
addiction specialized network. Hypothesizing that the ex-
pected retention rate will be 50 % in the intervention
group is very conservative. Actually, with an expected re-
tention rate of 60 % (as observed in our previous study) or
with an expected relative risk of 0.3-0.4 in favour of the
intervention group (as observed in the McCowan study
[28], with a benefit of performing urinary testing -what-
ever the results- on mortality in patients treated by metha-
done in UK). With this retention rate, only 34 clusters
should be needed, corresponding to 34 GPs in each group,
68 in the all sample, and consecutively 136 patients. This
hypothesis should be probably optimistic but not com-
pletely unrealistic.
This strategy will allow to overcome the proper effect
of each GP, to get enough clusters for the analysis and to
regroup clusters (on the basis of the same geographic
area (in French “Bassins de santé”) giving a sufficient
number of individuals in each cluster (5 subjects).
The Fig. 1 summarizes the design of the study.
Statistical analysis
Patients, will be analyzed according to the intervention
assigned to their GPs, whether being exposed to OS-
UDS during their participation or not, in accordance
with the intention-to-treat principle.
For patients followed up until the end of the study, the
retention rate will be the percentage of patients still
under OMT (complete data). For loss of follow up pa-
tients, an intention to treat approach will be used and
loss of follow will be analyzed as failure.
A description of the baseline characteristics of the
group will be performed, comprising mean ± SD for con-
tinuous variables and frequency and percentages for
qualitative variables. Baseline characteristics and second-
ary outcomes will be compared among groups using the
Chi2 test of independency or Fisher test for categorical
variables and the Student t test or the Wilcoxon test for
continuous variables. A significance threshold of 5 % will
be applied for all the statistical analyses.
Retention at 6 months will be computed as an individ-
ual binary variable, and will be analyzed using mixed ef-
fect logistic regression, including GPs as a random effect
parameter. Potential confounders or explanatory vari-
ables at individual and cluster level will be included. An
alternative way for analysis would consist in applying
generalized estimating equation (GEE). These models
are appropriate in the study design as the number of
cluster will be higher than 15 [43].
Univariate analyses on baseline variables as potential
predictors for success or failure of OMT maintenance
will be performed using Chi-square statistics for categor-
ical and Student t-test for continuous data. Variables
with a P-value of <0.2 after univariate analysis will be en-
tered into a multivariate logistic regression model. Crude
and adjusted Odds Ratio (OR) and their confidence in-
tervals will be estimated. The main analysis will be com-
pleted by univariate and multivariate clustered survival
analyses.
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Analyses will be performed using the SAS ® 9.3 soft-
ware (SAS Institute Inc., Cary, NC, USA).
Ethical approval
The study will be done in the French regulatory context
of standard care (in French “Soins Courants”), all the
procedures used in the study being in the standard care
of opiate addicts. Thus, the study will not modify the
standard follow-up of patients newly treated by an OMT
and all the medical visits and/or other interventions will
be done as needed.
This study has been approved by Persons’ Protection
Committee (CPP) of Bordeaux, France (n°2014-A00393-
44) and the Consultative Committee on Data Processing
in Research in the Area of Health (CCTIRS) (n°14.356bis).
Data treatment was authorized by the National Commis-
sion for Computing and Civil Liberties (CNIL) (applica-
tion n°915030, decision DR-2015-112).
The French Ministry of Health funded the project after
peer-reviewing the protocol. The body organization had
no role in the writing of the manuscript.
Discussion
This randomized intervention trial in primary care context
should bring sufficient level of evidence to assess effective-
ness of performing OS-UDS in general practice for pa-
tients treated by buprenorphine. The aim is to assess the
impact of a global intervention, including a better know-
ledge of UDS (through a specific GP’s training to perform
UDS and interpret their results), and giving the opportun-
ity to perform OS-UDS for any patient consulting for an
OMT initiation in the medical office by the GP. The better
way to assess this impact with a sufficient level of evidence
is to perform a randomized intervention trial in primary
care context, comparing OMT retention at 6 months in
patients cared by GPs randomly assigned to having on-site
UDS, compared to patients cared by GPs randomly
assigned to performing standard care.
Most of OMT patients in France are managed in the
context of primary care, whereas most of OMTclinical as-
sessments have been done in the context of specialized
centers. UDS should be used in this context of primary
care, but are rarely done. Commercial kits are giving the
possibility to perform UDS extemporarily in the medical
office. The limits of these tests in terms of sensitivity and
specificity are well-known, and this project does not aim
to assess the intrinsic validity of these tests, assuming that
they present a sufficient quality to be licensed in France,
but to assess effectiveness of performing OS-UDS in gen-
eral practice for patients treated by buprenorphine.
The widespread use of UDS is already a reality for some
(few) GPs working in specialized addiction networks and
in centers without laboratories inside. However, outside
this context, urine testing is rare and knowledge of GPs
remains scarce. Demonstrating the positive impact of OS-
UDS on GPs’ practice (in managing patients) and behav-
iors of patients treated with buprenorphine in general
practice (adherence) would be an important issue in the
field of opioid addiction care.
Training GPs to drug tests and supplying OS-UDS in
their office should lead to an improvement of opioid-
addicted patients’ care through helping decision making
Fig. 1 Design of the ESUB-MG pragmatic randomized controlled trial
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in the GP medical office, improving GPs’ practices, im-
proving adherence of treated patients, and consequently,
improving short and long term outcomes of OMT.
Trial status
Inclusions of GPs and patients will begin from January
2016 to March 2016 according to French regions. At the
time of manuscript submission, the ESUB-MG study is
ready to include GPs and patients. GPs’ inclusions are
expected to continue until August 2016. Patients’ inclu-
sions are expected to continue until January 2018. Data
collection is expected to continue until July 2018.
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